01. Product portfolioProTransStudy TeamCellaviva
02. About NextCellBusiness ConceptVision, mission, strategyHistory
OrganisationCompany Structure
03. InvestorsTO2 2025 / Rights Issue 2024NextCell as an investmentFinancial CalendarFinancial ReportsCorporate GovernanceCertified AdviserThe ShareArchive
04. NewsPress ReleasesNextCell in the mediaEventsCompany PresentationsQ&A with CEO
05. ContactContact InformationSubscribe
English
/
Svenska

NextCell´s publication of the phase I/II clinical trial in type I diabetes accepted

March 28, 2023

NextCell Pharma AB (”NextCell” or ”Company”) have had their article detailing the results of their phase I/II clinical trial in type I diabetes accepted in the peer-reviewed journal Diabetologia.

NextCell Pharma AB (”NextCell” or ”Company”) have had their article detailing the results of their phase I/II clinical trial in type I diabetes accepted in the peer-reviewed journal Diabetologia.

NextCell Pharma AB is a cell therapy company working in the development and commercialization of the mesenchymal stromal cell therapy product, ProTrans. This product, with its proprietary platform technology, is in clinical development for the treatment of autoimmune conditions, such as type I diabetes and inflammatory conditions such as viral pneumonia.

 

NextCell´s seminal study in type 1 diabetes, with their advanced therapeutic medicinal product, ProTrans, has been accepted for publication in the journal Diabetologia. The article, entitled, “Umbilical Cord-Derived Mesenchymal Stromal Cells Preserve Endogenous Insulin Production in Type 1 Diabetes: a Phase I/II Double-blinded, Placebo-controlled, Randomized trial” details how a single infusion of ProTrans can maintain the endogenous production of insulin, slowing the progression of the disease.

 

“It is fantastic to have our first study in type I diabetes published. This study has been the foundation for our clinical development programme in type I diabetes. The study, although small, presents strong data indicative of the effectiveness of ProTrans treatment in slowing diabetic disease development. Based on these data we have moved forward with a pediatric study investigating the efficacy of our drug product in newly diagnosed type I diabetics in the 7-21 age range, ”says Dr Mathias Svahn, CEO for NextCell Pharma.

 

The data reported in the manuscript was generated in collaboration with Professor Per-Ola Carlsson, Principal Investigator at Uppsala University and Karolinska Trial Alliance, Karolinska University Hospital, Huddinge, Sweden(Clinicaltrials.gov identifier NCT03406585).

 

For more information about NextCell Pharma AB, please contact:
Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel:08-735 5595
E-mail: info@nextcellpharma.com
Website: www.nextcellpharma.com
 LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma
 
 
 
About NextCell Pharma AB
NextCell is a celltherapy company in clinical phase II. The company has developed a proprietary and patented platform technology to produce mesenchymal stromal cells adapted for allogeneic treatment of various autoimmune and immunological diseases. The drug candidate ProTrans is now being tested for the treatment of type-1 diabetes as well as respiratory complications caused by Sars-CoV-2 infection. The focus is to take ProTrans to market approval for type-1 diabetes via a phase III study. ProTrans is evaluated in two clinical COVID-19 studies, in Sweden and Canada. NextCell is working on completing its own GMP facility for the manufacture of ProTrans. The GMP facility is expected to be ready for manufacturing smaller quantities of ProTrans in 2023. NextCell also owns 8.5%of FamicordTX, a start-up company in CAR-T and oncology, and 100% of Cellaviva, Scandinavia's largest stem cell bank for family savings of stem cells from umbilical cord blood and umbilical cord tissue with permission from the Swedish Health and Social Care Inspectorate (IVO).

 

‍

For more information about NextCell Pharma AB, please contact

Mathias Svahn, CEO
Patrik Fagerholm, CFO

Tel:08-735 5595
E-mail: info@nextcellpharma.com

Website: www.nextcellpharma.com

 LinkedIn: https://www.linkedin.com/company/15255207/

Twitter: https://twitter.com/NextCellPharma

‍

About NextCell Pharma AB

NextCell is a celltherapy company in clinical phase II. The company has developed a proprietary and patented platform technology to produce mesenchymal stromal cells adapted for allogeneic treatment of various autoimmune and immunological diseases. The drug candidate ProTrans is now being tested for the treatment of type-1 diabetes as well as respiratory complications caused by Sars-CoV-2 infection. The focus is to take ProTrans to market approval for type-1 diabetes via a phase III study. ProTrans is evaluated in two clinical COVID-19 studies, in Sweden and Canada. NextCell is working on completing its own GMP facility for the manufacture of ProTrans. The GMP facility is expected to be ready for manufacturing smaller quantities of ProTrans in 2023. NextCell also owns 8.5%of FamicordTX, a start-up company in CAR-T and oncology, and 100% of Cellaviva, Scandinavia's largest stem cell bank for family savings of stem cells from umbilical cord blood and umbilical cord tissue with permission from the Swedish Health and Social Care Inspectorate (IVO).

Download attachmentRead full press release on Cision (external link)
2025-12-09
NextCell in Swedish Life Science Delegation to Hong Kong
NextCell Pharma AB (“NextCell” or “the Company”) is participating in the Swedish life science delegation to Hong Kong on 10–12 December 2025, organised by the Hong Kong Chamber of Commerce in Sweden and the Hong Kong Biotechnology Organisation (HKBIO). The delegation brings together leading Swedish companies to deepen collaborations in research, clinical development, industrial production, and investment in Hong Kong and the Greater Bay Area (GBA).
Read moreRead more
2025-12-02
NextCell initiates collaboration with OptiCell – strengthening its cell-handling operations
NextCell Pharma AB (“NextCell” or “the Company”) has entered into a collaboration agreement with OptiCell Solutions AB (“OptiCell”) regarding the handling, freezing, storage, and transport of cell products used for research and development. The collaboration enables NextCell to further leverage its existing infrastructure and expertise in advanced cell handling, also beyond its own clinical projects.
Read moreRead more
2025-11-20
NextCell Pharma appoints Eric Gustafsson as new CFO
NextCell Pharma AB (“NextCell” or “the Company”) today announces the appointment of Eric Gustafsson as Chief Financial Officer (CFO). With extensive experience in leading financial transformations and industrial expansion phases within the pharmaceutical industry, Eric brings both strategic and operational expertise that will further strengthen NextCell’s continued growth and development.
Read moreRead more
2025-11-19
NextCell Pharma company presentations
NextCell Pharma AB's ("NextCell" or the "Company") CEO Mathias Svahn gave a presentation at the BioStock Life Science Summit 2025 in Lund on November 13[th]. He will also present at Redeye Theme: Autoimmune and Inflammatory Diseases Event later today at 13:05.
Read moreRead more
2025-10-30
NextCell Pharma publishes its Interim Report 4 2024/2025
NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 4 for the period June 1, 2025 – August 31, 2025. The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year. . Please note that the Company's financial year is now 1 January - 31 December. This means that for the year 2025, this Q4 report will be followed by a Year-end report at the end of February 2026, covering the period September-December 2025.
Read moreRead more
2025-09-18
NextCell Pharma AB announces CFO transition
NextCell Pharma AB (“NextCell” or the “Company”) today announces that the Company’s CFO, Patrik Fagerholm, has decided to step down to take on a new assignment. Patrik will remain in his role throughout the notice period to ensure a smooth transition. The recruitment process to identify a successor for the CFO position has been initiated.
Read moreRead more
2025-07-24
NextCell Pharma publishes its Interim Report 3 2024/2025
NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 3 for the period March 1, 2025 – May 31, 2025. This English version of the Interim Report is a translation of the Swedish version. The Swedish version is the official version. The report is available on the company's website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.
Read moreRead more
2025-07-14
NextCell Highlighted in FUJIFILM’s Strategic Vision, According to GEN
NextCell Pharma AB (“NextCell” or “the Company”) is pleased to announce that its strategic collaboration with FUJIFILM Biosciences has been highlighted in an article published on 8 July by Genetic Engineering & Biotechnology News (GEN). The article covers FUJIFILM’s recent rebranding and long-term ambition to act as a full-spectrum partner to drug and vaccine developers throughout the entire development cycle.
Read moreRead more
This website uses cookies in order to improve the user experience. Read more
Preferences
DenyAccept